Vertebral osteomyelitis: Difference between revisions

From IDWiki
mNo edit summary
mNo edit summary
 
(5 intermediate revisions by the same user not shown)
Line 1: Line 1:
==Background==
= Microbiology =


===Microbiology===
* ''Staphylococcus aureus''
* ''Brucella'', in patients from endemic countries, can be as high as 25% of cases


*[[Staphylococcus aureus]]
= Management =
*Other [[Gram-positive cocci]], including [[viridans group streptococci]], [[Streptococcus bovis]], [[enterococci]], [[Streptococcus agalactiae]], group C and G [[streptococci]]
*Less commonly, [[coagulase-negative staphylococci]], [[Gram-negative bacilli]], including [[Pseudomonas aeruginosa]], and [[Candida]], especially in patients with indwelling lines or injection drug use
*[[Tuberculosis]]
*[[Brucella melitensis|Brucella]], in patients from endemic countries, can be as high as 25% of cases


==Management==
* IV or highly bioavailable oral (metronidazole, fluoroquinolones, linezolid, TMP-SMX, clindamycin, and doxycycline/rifampin)
** Can double-cover ''Enterococcus'' with an aminoglycoside for 4 to 6 weeks
* Duration: 6 weeks for most, but 3 months for ''Brucella''
*


*IV or highly bioavailable oral ([[metronidazole]], [[fluoroquinolones]], [[linezolid]], [[TMP-SMX]], [[clindamycin]], and [[doxycycline]]/[[rifampin]])
== ''Brucella'' ==
**Can double-cover ''[[Enterococcus]]'' with an [[Aminoglycosides|aminoglycoside]] for 4 to 6 weeks
*Duration: 6 weeks for most, but 3 months for ''[[Brucella]]''


===''Brucella''===
* Doxycycline/rifampin
* Duration: 3 months


*Combination of [[doxycycline]] and [[rifampin]]
= Prognosis =
*Duration: 3 months


=== With Orthopedic Hardware ===
* Cure rates are 70-90% with 6 weeks of antibiotics, and are ''not'' higher with longer durations (per a single RCT)

* Poor prognosis is associated with multidisc disease, the presence of concomitant epidural abscess, lack of surgical therapy, infection with ''S. aureus'', old age, or the presence of significant comorbidities
* Often treated with retention of hardware, especially in early-onset disease[[CiteRef::atesok2020fa]]
* Early onset (<4 to 6 weeks post-op)
** I&D with retention of hardware and bone graft material, with primary closure instead of a drain, if feasible
* Late onset (more than 4 to 6 weeks post-op)
** Fusion achieved: incision and drainage with removal of hardware
** Fusion not achieved: retention of hardware with suppressive antibiotics until fusion is achieved, then removal of hardware

==Prognosis==

*Cure rates are 70-90% with 6 weeks of antibiotics, and are ''not'' higher with longer durations (per a single RCT)
*Poor prognosis is associated with multidisc disease, the presence of concomitant epidural abscess, lack of surgical therapy, infection with ''S. aureus'', old age, or the presence of significant comorbidities


[[Category:Bone and joint infections]]
[[Category:Bone and joint infections]]

Latest revision as of 23:17, 12 March 2022

Background

Microbiology

Management

Brucella

With Orthopedic Hardware

  • Often treated with retention of hardware, especially in early-onset disease1
  • Early onset (<4 to 6 weeks post-op)
    • I&D with retention of hardware and bone graft material, with primary closure instead of a drain, if feasible
  • Late onset (more than 4 to 6 weeks post-op)
    • Fusion achieved: incision and drainage with removal of hardware
    • Fusion not achieved: retention of hardware with suppressive antibiotics until fusion is achieved, then removal of hardware

Prognosis

  • Cure rates are 70-90% with 6 weeks of antibiotics, and are not higher with longer durations (per a single RCT)
  • Poor prognosis is associated with multidisc disease, the presence of concomitant epidural abscess, lack of surgical therapy, infection with S. aureus, old age, or the presence of significant comorbidities

References

  1. ^  Kivanc Atesok, Alexander Vaccaro, Martina Stippler, Brendan M. Striano, Michael Carr, Michael Heffernan, Steven Theiss, Efstathios Papavassiliou. Fate of Hardware in Spinal Infections. Surgical Infections. 2020;21(5):404-410. doi:10.1089/sur.2019.206.